We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Collaboration of Mayo Clinic and IBM Cognitive Computer Devised to Improve Clinical Trial Research

By LabMedica International staff writers
Posted on 21 Sep 2014
Print article
The Mayo Clinic (Rochester, MN, USA) and IBM (Armonk, NY, USA) recently announced plans to pilot Watson, the IBM cognitive computer, to match patients more rapidly with suitable clinical trials.

A proof-of-concept phase is currently ongoing, with the intent to introduce it into clinical use in early 2015. “In an area like cancer, where time is of the essence, the speed and accuracy that Watson offers will allow us to develop an individualized treatment plan more efficiently so we can deliver exactly the care that the patient needs,” stated Steven Alberts, MD, chair of medical oncology at Mayo Clinic. The researchers hope the increased speed also will speed new discoveries.

Clinical trials provide patients with access to new and emerging treatments; however, enrolling participants in trials is one of the more problematic areas of clinical research. Currently it is done manually, with clinical coordinators sifting through patient records and conditions, trying to correlate them with the requirements of a given study protocol. At any given time, Mayo Clinic is conducting over 8,000 human studies in addition to the 170,000 that are ongoing worldwide. Watson’s cognitive computing ability will help sift through available Mayo clinical trials and ensure that more patients are effectively and consistently matched with promising clinical trial options.

“With shorter times from initiation to completion of trials, our research teams will have the capacity for deeper, more complete investigations,” said Nicholas LaRusso, MD, a Mayo Clinic gastroenterologist and the project lead for the Mayo-IBM Watson collaboration. “Coupled with increased accuracy, we will be able to develop, refine, and improve new and better techniques in medicine at a higher level.”

This version of Watson will be expressly designed for Mayo Clinic. As it progresses in its tasks and matures through this collaboration, it will learn more about the clinical trials matching process, become even more efficient and likely more generalizable. The Watson computer also may help locate patients for hard-to-fill trials, such as those involving rare diseases.

Many clinical trials at Mayo Clinic and elsewhere are not completed due to lack of sufficient enrollment. Enrollment in general could be increased by the Watson project. In spite of well-organized efforts, even at Mayo Clinic, only 5% of patients take part in studies. In the United States, the rate is even lower, at 3%. Mayo hopes to raise clinical trial involvement to include up to 10% of its patients. Researchers say the higher participation also should improve the quality of research outcomes.

“Using Watson’s cognitive computing capabilities, Mayo Clinic can consistently offer more cutting-edge medical options to patients and conclude trials faster,” said Mike Rhodin, senior vice president, IBM Watson Group. “Ultimately, this effort will also help advance scientific discoveries into promising new forms of care that clinicians can use to treat all patients.”

To make sure that Watson has the required know-how to help with clinical trial matching, Mayo specialists are working with IBM to expand Watson’s body of knowledge to include all clinical trials at Mayo Clinic and in public databases, such as ClinicalTrials dot gov. The new Watson system is being trained to examine patient records and clinical trial criteria to determine appropriate matches for patients.

Mayo and IBM are deliberating on other applications for Watson in the future.

Related Links:

Mayo Clinic
IBM
IBM Watson Cognitive Computer


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read more

Pathology

view channel
Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF)

New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.